The Estée Lauder Companies Strengthens Its Global Fulfillment Network with the Opening of a New, State-of-the-Art Galgenen Distribution Center Dedicated to the Travel Retail Channel
7.6.2022 16:00:00 EEST | Business Wire | Press release
The Estée Lauder Companies (ELC) today announced the opening of its new, state-of-the-art distribution center located in Galgenen, Switzerland to accommodate the dynamic and future growth of its global Travel Retail business. Travel Retail, which covers the world of duty-free environments including airports, downtown locations, airlines, cruises and border shops, is one of the company’s highest growth channels and touches over 3 billion consumers a year. This new 300,000 square foot facility expands upon the company’s existing distribution footprint in Switzerland and will enable ELC to remain at the forefront of delivering its prestige beauty products and high-touch services to traveling consumers around the world. The center is equipped to support the continued growth of Travel Retail and will further drive the company's sustainability efforts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005792/en/
Umair Ansari, VP/GM, Travel Retail EMA, Fabrizio Freda, President and Chief Executive Officer, Jane Lauder, EVP, Enterprise Marketing and Chief Data Officer, and Roberto Canevari, EVP, Global Supply Chain cut the ribbon at the new Galgenen distribution center. (Photo: Business Wire)
Fabrizio Freda, President and Chief Executive Officer, Israel Assa, Global President, Travel Retail Worldwide and Roberto Canevari, Executive Vice President, Global Supply Chain hosted the opening ceremony with Nadine Graf, Senior Vice President, General Manager, Europe, Middle East, and Africa (EMEA), Maike Kiessling, General Manager, Switzerland, Jamal Chamariq, Senior Vice President, Global Supply Chain, EMEA and Travel Retail Worldwide and Sascha Trabelsi, Vice President, Supply Chain, Travel Retail Worldwide. The opening ceremony was attended by special guests including retailers, suppliers, local government officials, media and ELC employees.
“Travel Retail continues to demonstrate its resilience, driving tremendous growth over the last decade for The Estée Lauder Companies. We remain extremely confident in the channel for the long-term, especially as travel restrictions ease globally and people start traveling again,” said Fabrizio Freda. “The opening of our new Galgenen distribution center will enable us to adapt even better to ever-changing retail needs and growth opportunities for the channel, and expand upon our existing distribution presence in Switzerland.”
The Estée Lauder Companies’ Travel Retail division is the market share leader in the channel within the total beauty category across skin care, makeup, fragrance and hair care1. With a strong brand portfolio that resonates with consumers globally, ELC’s Travel Retail division continually demonstrates best-in-class marketing activations tailored to travelers’ needs, recruits new consumers and builds brand equity around the world. Accounting for 28% of ELC’s sales in fiscal year 2021, Travel Retail is uniquely positioned to win in this high growth environment with the company’s recent investment to expand its distribution network to meet the demands of the traveling consumer population.
“As we mark the 30th anniversary of The Estée Lauder Companies’ Travel Retail business, we are incredibly proud of our track record of exciting and delighting travelers all over the world with our exclusive products and high-touch experiences for the Travel Retail industry and having made the channel an integral engine of growth for ELC,” said Israel Assa. “As we look to the future, this investment here at Galgenen is a testament to our belief in the long-term growth potential of this channel and that by investing in these capabilities and with our retailers, we can capture the next generation of growth in this dynamic, prestige marketplace.”
The Estée Lauder Companies has a long history of success within Switzerland, opening its affiliate office more than 55 years ago and its first manufacturing plant more than 45 years ago. As the fifth largest employer in the canton of Schwyz, ELC prides itself on its inclusive and collaborative culture, competitive compensation and benefits, career development opportunities, commitments to health, safety and sustainability, and high-performance. The company currently has four distribution centers in Switzerland. Switzerland is also home to ELC’s EMEA and TR Supply Chain Management Hub in Wollerau, which drives agility, speed, and collaboration across our EMEA and Travel Retail supply chain teams. With the addition of the new facility in Galgenen, the Travel Retail business will double its total output capacity, enabling the flexibility necessary to adapt to the channel’s high growth potential.
“Galgenen will serve as a cornerstone of The Estée Lauder Companies’ agile, global fulfillment network,” said Roberto Canevari. “This distribution center will not only significantly enhance our capacity but enable operational efficiencies, speed-to-market and resiliency through innovative, highly automated equipment and technologies. Additionally, we are proud that Galgenen is also a shining example of ELC’s commitment to safety, quality, and sustainability.”
Galgenen will further advance the sustainability of ELC’s global manufacturing and distribution network and the company through its best-in-class environmental design and renewable energy efforts. The building’s design is based on the newest standards to reduce energy and water consumption. It features total LED lighting, an energy-efficient HVAC system and the roof’s solar panels generate 1600 kilowatts at peak performance (kWp). Furthering sustainability efforts, a comprehensive waste management system has been implemented to separate out numerous recyclables, with electric trucks ready for waste removal. As part of the recycling undertaking, wooden waste pallets will generate renewable heating energy. Worldwide, ELC is driving strategic initiatives to reduce its environmental footprint, integrate environmentally responsible practices and invest in innovative technology as part of efforts to not only provide consumers with transformative products and experiences, but also to contribute to the well-being of the planet.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced and Dr. Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
[1] Generation Research 2020
ELC-C
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005792/en/
Contact information
Colleen T. Leahy
cleahy@estee.com
Jill Marvin
jimarvin@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
